We are dedicated to developing innovative antiviral intranasal inhibitors for better pandemic preparedness and prevention.
Protection against a broad-spectrum of viruses
Respiratory viral infections represent a major disease burden globally through their impact on healthcare, society and economies. Nature encompasses a vast reservoir of yet unknown viruses that can be grouped into a few dozen viral families. In addition, new variants of known viruses emerge upon transmission in humans. We do not know, however, which one of them challenges us next and how severely. Therefore, new preventive and affordable antiviral approaches are needed.
Pandemblock Ltd is a University of Helsinki spin-out biotechnology company established in fall 2021.
We are working determinedly to advance our first product Covidin, an intranasal prophylactic and early therapeutic candidate against SARS-CoV-2, into the clinic.
Our VISIONis a world better prepared
for viral pandemics and epidemics.
Our MISSION is to provide preventive and
affordable intranasal antiviral protection
for people globally.
Targeting the Achilles heel of viruses
Using Pandemblock's targeting technology, the blocking of virus infection is directed to a structural site that is common between all variants within a viral strain or family, thus likely including yet unknown future variants. Typically these highly conserved structures - Achilles heels - are pivotal to viral life cycle and transmission. In this way the members of an entire virus family can be blocked by one solution.
at the site of infection
Pandemblock's proprietary Sherpabody-platform provides virus-specific nasal sprays that act as a biological mask in the nasal cavity i.e. at the site where the viral infection and amplification initially occurs. By directly inactivating the target virus, our nasal sprays offer immediate and robust protection against viral infections and inhibit viral spread between people.
Offering protection independent of immunity
Our nasal spray products are administered into the nasal cavity providing instant protection against viral infection. The inhibitory action does not depend on person's own immune system, and therefore can offer a first line of defense also for vulnerable people including elderly and immunocompromised persons. Vaccinated people equally benefit from not catching breakthrough infections and disease.